Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 6

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 6
---
 and are qualified
in their entirety by reference to the full text of such agreements, copies of which are attached hereto as Exhibits 10.1 and 10.2, respectively,
and each of which is incorporated herein in its entirety by reference. The representations, warranties and covenants contained in such
agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such
agreements and may be subject to limitations agreed upon by the contracting parties.

| 3 |

In
the Purchase Agreement, the Purchaser represented to the Company, among other things, that it is an “accredited investor”
(as such term is defined in Rule 501(a)(3) of Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities
Act”)). The securities referred to in this Report on Form 6-K are being issued and sold by the Company to the Purchaser in reliance
upon the exemptions from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and Rule
506(b) of Regulation D promulgated thereunder. The securities may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements. Neither this Report on Form 6-K, nor the exhibits attached hereto, is an offer to
sell or the solicitation of an offer to buy the securities described herein.

<div align='center'>SUBMITTED HEREWITH</div>

Attached to the Registrant’s Form 6-K filing for the month of January
2025, and incorporated by reference herein, is:

| * | Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit 
 will be furnished to the SEC upon request.                                                                                           |

| 4 |

<div align='center'>SIGNATURES</div>

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

| Date:  January 17, 2025 | Biodexa Pharmaceuticals 
 PLC                     
 By:                     | /s/ Stephen Stamp                 |
|:------------------------|:------------------------|:----------------------------------|
|                         |                         | Stephen Stamp                     |
|                         |                         | Chief Executive Officer and Chief 
 Financial Officer